Kinetics of serum cytokines reflect changes in the severity of chronic hepatitis C presenting minimal fibrosis

No abstract is available for this paper.

• Publication year

  2002

• Venue

  Journal of Viral Hepatitis

• Publication date

  2002-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1046/j.1365-2893.2002.00343.xPMID 11876796
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• EASL International Consensus Conference on Hepatitis B. 13-14 September, 2002: Geneva, Switzerland. Consensus statement (short version).

  2003cited by this paper
• Digestive Disease Week 2000 conference report: New treatments for chronic hepatitis C.

  2001cited by this paper
• Immunopathogenesis of hepatitis C viral infection: Th1/Th2 responses and the role of cytokines.

  2001cited by this paper
• Cytokines as predictors for sustained response and as markers for immunomodulation in patients with chronic hepatitis C.

  2001cited by this paper
• Hepatitis C virus genotypes and risk of cirrhosis in southern Italy.

  2001cited by this paper
• Sexual transmission of hepatitis C virus.

  2001cited by this paper
• Cytokine network in nonresponding chronic hepatitis C patients with genotype 1: role of triple therapy with interferon alpha, ribavirin, and ursodeoxycholate.

  2001cited by this paper
• Natural history of HCV infection.

  2000cited by this paper
• Pathogenesis, Natural History, Treatment, and Prevention of Hepatitis C

  2000cited by this paper
• Mother-to-child transmission of hepatitis C virus: evidence for preventable peripartum transmission.

  2000cited by this paper
• Low frequency of cirrhosis in a hepatitis C (genotype 1b) single‐source outbreak in germany: A 20‐year multicenter study

  2000cited by this paper
• Impact of interferon alfa‐2b and ribavirin on progression of liver fibrosis in patients with chronic hepatitis C

  2000cited by this paper
• Hepatocellular carcinoma occurring in nonfibrotic liver: Epidemiologic and histopathologic analysis of 80 French cases

  2000cited by this paper
• Predictors of sustained response to alpha interferon therapy in chronic hepatitis C.

  1999cited by this paper
• EASL International Consensus Conference on Hepatitis C

  1999cited by this paper
• EASL International Consensus Conference on Hepatitis C

  1999cited by this paper
• Combination therapy for chronic hepatitis C: interferon and ribavirin.

  1999cited by this paper
• Role of cytokines in ethanol-induced cytotoxicity in vitro in Hep G2 cells.

  1998cited by this paper
• Predictors of sustained response to alpha interferon therapy in chronic hepatitis C.

  1998cited by this paper
• Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT)

  1998cited by this paper
• Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus

  1998cited by this paper
• Tumor necrosis factor α gene expression and the response to interferon in chronic hepatitis C

  1996cited by this paper
• An algorithm for the grading of activity in chronic hepatitis C

  1996cited by this paper
• Laboratory measurement of human cytokines.

  1995cited by this paper
• Facteurs de réponse au traitement par l'interféron alpha chez les malades atteints d'hépatite chronique C. Perspectives thérapeutiques.

  1995cited by this paper
• Relationship of aminotransferases to liver histological status in chronic hepatitis C.

  1995cited by this paper
• [Factors of response to treatment with interferon-alpha in patients with chronic hepatitis C. Therapeutic perspectives].

  1995cited by this paper
• Sexual transmission of hepatitis C virus

  1991cited by this paper
• Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis

  1981cited by this paper
• Short Communication Mediators of Inflammation, 7, 295–297 (1998)

  year unknowncited by this paper

• Analysis of hepatic fibrosis markers in the serum of chronic hepatitis B patients according to basal core promoter/precore mutants

  2022cites this paper
• Inflammation and Liver Cell Death in Patients with Hepatitis C Viral Infection

  2021cites this paper
• Modifications of liver stiffness and CXCL4, TGF-β1 and HGF are similar in HCV- and HIV/HCV-infected patients after DAAs

  2021cites this paper
• Serum cytokines, adipokines and ferritin for non-invasive assessment of liver fibrosis in chronic liver disease: a systematic review

  2019cites this paper
• Investigating the hepatitis C virus and dengue virus interactions with host lipid pathways : from circulating human microRNAs to lipid modulating agents

  2016cites this paper
• CYTOKINES. THE MISSING SHACKLE IN CHRONIC HEPATITIS C DEVELOPMENT

  2016cites this paper
• Influence of cytokine and cytokine receptor gene polymorphisms on the degree of liver damage in patients with chronic hepatitis C

  2016cites this paper
• Acute and chronic immune biomarker changes during interferon/ribavirin treatment in HIV/HCV co‐infected patients

  2015cites this paper
• Journal of Pharmaceutical and Biological Sciences

  2015cites this paper
• Gender and liver

  2015cites this paper
• Alcoholic liver disease: a synopsis of the Charles Lieber's Memorial Symposia 2009-2012.

  2014cites this paper
• Ribavirin induced hemolysis: a novel mechanism of action against chronic hepatitis C virus infection.

  2014cites this paper
• Risk of infections of biological therapies with accent on inflammatory bowel disease.

  2014cites this paper
• Single-dose infliximab in hepatitis C genotype 1 treatment-naive patients with high serum tumour necrosis factor-alpha does not influence the efficacy of pegylated interferon alpha-2b/ribavirin therapy.

  2014cites this paper
• Differential expression of Toll-like receptors 7 & 8 mRNA in monocytes of patients with chronic hepatitis C infection: correlation with interferon and ribavirin treatment.

  2014cites this paper
• Clinical Significance and Functional Studies of Myeloid-Derived Suppressor Cells in Chronic Hepatitis C Patients

  2013cites this paper
• Modulation of innate immune responses by hepatitis C virus

  2012cites this paper
• Lack of short-term increase in serum mediators of fibrogenesis and in non-invasive markers of liver fibrosis in HIV/hepatitis C virus-coinfected patients starting maraviroc-based antiretroviral therapy

  2012influential citation
• Hormone replacement therapy in menopausal women: risk factor or protection to nonalcoholic fatty liver disease?

  2012cites this paper
• Vascular Endothelial Growth Factor ( VEGF ) and Transforming Growth Factor β 1 ( TGF-β 1 ) as Predictors of Hepatocellular Carcinoma in HCV Related Liver Cirrhosis

  2011cites this paper
• Early menopause is associated with lack of response to antiviral therapy in women with chronic hepatitis C.

  2011cites this paper
• Twelve potential fibrosis markers to differentiate mild liver fibrosis from cirrhosis in patients infected with chronic hepatitis C genotype 1

  2011cites this paper
• Markers of Inflammation and Fibrosis in Alcoholic Hepatitis and Viral Hepatitis C

  2011cites this paper
• Soluble inflammatory markers as predictors of liver histological changes in patients with chronic hepatitis C virus infection

  2010cites this paper
• Innate immunity and chronic immune activation in HCV/HIV-1 co-infection.

  2010cites this paper
• Soluble Angiogenesis Factors in Sera of Egyptian Patients with Hepatitis C Virus Infection: Correlation with Disease Severity

  2010cites this paper
• Université Victor Segalen Bordeaux 2

  2010cites this paper
• Lack of effect of tumor necrosis factor-alpha -308 G/A polymorphism on severity of liver fibrosis in Tunisian hepatitis C virus (HCV)-infected patients.

  2010cites this paper
• Soluble inflammatory markers as predictors of hepatocellular damage and therapeutic response in chronic hepatitis C.

  2009cites this paper
• Relation between Body Fat and Liver Fat Accumulation and Cytokine Pattern in Non-Alcoholic Patients with Chronic HCV Infection

  2009cites this paper
• NON INVASIVE EVALUATION OF LIVER FIBROSIS IN PATIENTS WITH CHRONIC HEPATITIS B AND C

  2009cites this paper
• The interaction of hepatitis C virus and intracellular lipid metabolism

  2008cites this paper
• Effect of Interferon-Alpha, Ribavirin, Pentoxifylline, and Interleukin-18 Antibody on Hepatitis C Sera-Stimulated Hepatic Stellate Cell Proliferation

  2008cites this paper
• Inflammation and Repair in Viral Hepatitis C

  2008cites this paper
• Clinicopathological and prognostic features of primary clear cell carcinoma of the liver

  2008cites this paper
• Disease-specific mechanisms of fibrosis: hepatitis C virus and nonalcoholic steatohepatitis.

  2008cites this paper
• Cytokines and lipid peroxidation in alcoholics with chronic hepatitis C virus infection.

  2008cites this paper
• Marcadores inflamatórios solúveis como preditores de alteraçõeshistologicas hepáticas e resposta terapêutica na infecção crônica pelovírus da hepatite C

  2008cites this paper
• Pathogenesis of Hepatitis C - HCV Consensus 2007

  2007cites this paper
• Hepatic steatosis in HIV-HCV coinfected patients in France : comparison with HCV monoinfected patients matched for body mass index and HCV genotype

  2007cites this paper
• Viral and host factors induce macrophage activation and loss of toll-like receptor tolerance in chronic HCV infection.

  2007cites this paper
• Viral Factors Associated with Cytokine Expression During HCV/HIV Co-Infection

  2007cites this paper
• Comparative profiling of circulatory levels of adipokines and cytokines in patients with various types of non alcoholic fatty liver disease

  2007cites this paper
• Hepatitis C and steatosis.

  2007cites this paper
• Oxidative‐inflammatory damage in cirrhosis: Effect of vitamin E and a fermented papaya preparation

  2007cites this paper
• Cytokine--chemokine and apoptotic signatures in patients with hepatitis C.

  2007cites this paper
• Genetics, Genomics, and Proteomics: Implications for the Diagnosis and the Treatment of Chronic Hepatitis C

  2007cites this paper
• Hepatic steatosis in HIV‐HCV coinfected patients in France: comparison with HCV monoinfected patients matched for body mass index and HCV genotype

  2007cites this paper
• Transforming growth factor‐β1 suppresses hepatitis B virus replication primarily through transcriptional inhibition of pregenomic RNA

  2007cites this paper
• Genetics, genomics, and proteomics: implications for the diagnosis and the treatment of chronic hepatitis C.

  2007cites this paper
• Prevalence of and Factors Associated With Hepatic Steatosis in Patients Coinfected With Hepatitis C Virus and HIV: Agence Nationale pour la Recherche contre le SIDA et les hépatites virales CO3 Aquitaine Cohort

  2007cites this paper
• Effects of HCV Treatment on Cytokine Expression During HCV/HIV Coinfection

  2006cites this paper
• Toll-like receptor expression in chronic hepatitis C: Correlation with pro-inflammatory cytokine levels and liver injury

  2006cites this paper
• Expression of Ki‐67, transforming growth factor β1, and B‐cell lymphoma–leukemia‐2 in liver tissue of patients with chronic liver diseases

  2006cites this paper
• Distinct Toll-like receptor expression in monocytes and T cells in chronic HCV infection.

  2006cites this paper
• Drug Interactions Between Psychoactive Substances and Antiretroviral Therapy in Individuals Infected With Human Immunodeficiency and Hepatitis Viruses

  2006influential citation
• Intrahepatic and peripheral T-cell responses in genotype 1b hepatitis C virus-infected patients with persistently normal and elevated aminotransferase levels.

  2005cites this paper
• Effect of pegylated interferon alpha 2b plus ribavirin treatment on plasma transforming growth factor-beta1, metalloproteinase-1, and tissue metalloproteinase inhibitor-1 in patients with chronic hepatitis C.

  2005cites this paper
• Liver gene expression signature of mild fibrosis in patients with chronic hepatitis C.

  2005cites this paper
• Suppression of hepatitis C virus replicon by TGF-beta.

  2005cites this paper
• Role of Liver Biopsy in Hepatic Fibrosis

  2005cites this paper
• Hepatitis C virus core variants isolated from liver tumor but not from adjacent non-tumor tissue interact with Smad3 and inhibit the TGF-beta pathway.

  2005cites this paper
• STEATOSIS IN CHRONIC HEPATITIS C: WHY DOES IT REALLY MATTER?

  2005cites this paper
• Hepatitis C virus core variants isolated from liver tumor but not from adjacent non-tumor tissue interact with Smad3 and inhibit the TGF-β pathway

  2005cites this paper
• Evaluation of Liver Fibrosis: A Concise Review

  2004cites this paper
• Tissue remodelling in liver diseases.

  2003cites this paper
• Tumor necrosis factor-alpha acts as a complete mitogen for primary rat hepatocytes.

  2003cites this paper
• Steatosis in hepatitis C: What does it mean?

  2003cites this paper
• Tumor Necrosis Factor-α Acts as a Complete Mitogen for Primary Rat Hepatocytes

  2003cites this paper
• Liver fibrosis is not associated with steatosis but with necroinflammation in French patients with chronic hepatitis C

  2003cites this paper
• Mechanisms of increased insulin resistance in non‐cirrhotic patients with chronic hepatitis C virus infection

  2003cites this paper
• Hepatitis C virus nonstructural protein 5A inhibits tumor necrosis factor-alpha-mediated apoptosis in Huh7 cells.

  2003cites this paper
• Etanercept therapy in patients with autoimmunity and hepatitis C

  2003cites this paper
• Protein metabolism in liver cirrhosis: from albumin to muscle myofibrils

  2003cites this paper
• HEPATITIS Liver fibrosis is not associated with steatosis but with necroinflammation in French patients with chronic hepatitis

  2003cites this paper
• Ageing: biology and nutrition Body composition and energy expenditure in ageing Related review: Body composition in aging: a biological perspective (pp 15–20)

  2002cites this paper
• Cytokines and their antagonists as therapeutic agents.

  2002cites this paper